<

ADOLORE BIOTHERAPEUTICS, INC. Adolore BioTherapeutics to Present at the Virtual Investor Pitch Conference

Transparency directive : regulatory news

10/06/2024 15:15

Live video webcast on Monday, June 17th at 10:00 AM ET

DELRAY BEACH, FL / ACCESSWIRE / June 10, 2024 / Adolore BioTherapeutics ("Adolore" or the "Company"), a biotechnology company focused on developing breakthrough opioid-free gene therapy treatments for chronic pain, today announced that it will present at the Virtual Investor Pitch Conference on June 17, 2024 at 10:00 AM ET.

As part of the event, Roelof Rongen, CEO of Adolore, will provide an "elevator pitch" and outline the Company's upcoming milestones. Additionally, investors and interested parties will have the opportunity to submit questions live during the event. Participating companies will answer as many questions as possible in the time allowed.

A live video webcast will be accessible on the event website, virtualinvestorco.com. A webcast replay will be available two hours following the live presentation and will be accessible for 90 days.

About Adolore Biotherapeutics

Adolore BioTherapeutics, Inc., is a biotechnology company focused on developing novel therapies for the treatment of chronic pain and other pain and nervous system conditions or disorders. Our best-in-class programs are long-acting, locally acting gene-therapies that are opioid-free Disease Modifying Anti-Pain therapies (DMAPs) designed to treat many forms of chronic pain.

The Company's current CA8* gene therapy programs are in preclinical development for treatment of patients suffering from erythromelalgia, a life-long heritable chronic pain condition representing an orphan drug disease with no approved therapy, and chronic pain due to knee osteoarthritis, affecting a large number of patients that are often treated with opioids due to the lack of good alternatives, thus contributing to the ongoing opioid crisis.

For more information, visit adolore.com.

INVESTOR CONTACT:

Jenene Thomas, JTC Team, LLC
adolore@jtcir.com
(833) 475-8247

SOURCE: Adolore Biotherapeutics, Inc.



View the original press release on accesswire.com



Other stories

13/06/2024 04:42
13/06/2024 03:30
13/06/2024 04:04
13/06/2024 03:22
13/06/2024 01:30
12/06/2024 20:06
12/06/2024 14:28
12/06/2024 19:22
12/06/2024 15:14
11/06/2024 03:31
13/06/2024 03:08
12/06/2024 18:47
12/06/2024 14:34
13/06/2024 03:30
12/06/2024 20:04
12/06/2024 20:11
12/06/2024 13:30
12/06/2024 20:48
13/06/2024 00:36
12/06/2024 18:23
11/06/2024 08:44
12/06/2024 19:36
12/06/2024 21:00
11/06/2024 11:04
13/06/2024 01:01
12/06/2024 18:00
13/06/2024 03:30
12/06/2024 23:31
12/06/2024 20:56
12/06/2024 19:01
12/06/2024 22:29
11/06/2024 17:23
13/06/2024 05:06
12/06/2024 17:45
13/06/2024 05:36
13/06/2024 01:29
13/06/2024 03:30
12/06/2024 16:46